The study will evaluate the safety and tolerability, optimal biologic dose, and pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet count and are receiving ADRIAMYCIN and ifosfamide (AI) chemotherapy.

Inclusion criteria:

• Adult subjects, 18 years or older
• Adequate liver and kidney function
• Prior history of ≥grade 2 thrombocytopenia (platelet nadir ≤ 75,000/microliters)
• Ability to ingest and retain oral medication
• Practice acceptable birth control
• Ability to understand and follow study requirements
• Life expectancy of at least 3 months

Exclusion criteria:

• History of platelet disorders, dysfunction, or a bleeding disorder
• Anti-coagulant used within 2 weeks prior to study start
• Females who are lactating or expecting
• History of thromboembolic events or drug induced thrombocytopenia
• History of central nervous system, brain and/or leptomeningeal metastases
• Prior surgery within 2 weeks or radiotherapy within 4 weeks of study start
• Pre-existing cardiac disease